Mirion appoints Michael Rossi as Medical Group President; he joins from Novartis

Mirion Technologies, Inc.

Michael Rossi appointed President of Mirion Medical, reporting to CEO Tom Logan.
Rossi previously Head of Radioligand Imaging at Novartis' Advanced Accelerator Applications.
Employment terms: base salary $470,000, target bonus 60% of base, initial RSUs valued at $650,000.
CEO Tom Logan had been acting as Medical segment President; Rossi to drive organic/inorganic growth.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Rossi

Medical Group President

MIR · Mirion Technologies, Inc.

Effective: 2022-10-03
Filed: October 3, 2022, 7:59 PM ET

On October 3, 2022, Mirion Technologies, Inc. (the “Company”) announced the appointment of Michael Rossi, as Medical Group President of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Rossi was appointed as Medical Group President at Mirion Technologies, Inc..

Action: appointed
Role: Medical Group President

Exact text from the filing

On October 3, 2022, Mirion Technologies, Inc. (the “Company”) announced the appointment of Michael Rossi, as Medical Group President of the Company.

View on SEC.gov

Mirion Technologies, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-025820

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.